Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
News|Articles|April 10, 2017
Weirless Diaphragm Valves Eliminate Cross-Contamination
Watson-Marlow Fluid Technology Group’s ASEPCO Weirless Radial diaphragm valves eliminate dead legs and product entrapment.
Watson-Marlow Fluid Technology Group (WMFTG)’s ASEPCO Weirless Radial diaphragm valves use integral travel stops and a patented radial shoulder seal to completely isolate process fluids and eliminate dead legs and cross-contamination. Unlike weir-style diaphragm valves, which can introduce product entrapment and leakage, the weirless valves are contamination-free and feature a 180° flow path, with drainability in multiple orientations without leakage.
The weirless valves feature a clean, self-draining design with a simple clamp assembly that reduces change time from as much as 20 minutes (with a typical weir-type valve) down to a minute. The valves are easy to seal and inspect and never need retightening or adjustment. No tools are required for maintenance.
The valves offer installation flexibility for compact skids; more compact systems require less time to get up to temperature and achieve sterilization, thus improving efficiency of biopharmaceutical processes. Actuators on the valves have numerous options, including a control interface that enables users to use the weirless valve to control flow in process lines.
Source: Watson-Marlow Fluid Technology Group
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.